GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SSY Group Ltd (HKSE:02005) » Definitions » Beta

SSY Group (HKSE:02005) Beta : 0.65 (As of May. 02, 2024)


View and export this data going back to 2005. Start your Free Trial

What is SSY Group Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-02), SSY Group's Beta is 0.65.


SSY Group Beta Historical Data

The historical data trend for SSY Group's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SSY Group Beta Chart

SSY Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.37 1.13 0.93 0.58 0.57

SSY Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.93 0.54 0.58 0.64 0.57

Competitive Comparison of SSY Group's Beta

For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SSY Group's Beta Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SSY Group's Beta distribution charts can be found below:

* The bar in red indicates where SSY Group's Beta falls into.



SSY Group Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


SSY Group  (HKSE:02005) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


SSY Group Beta Related Terms

Thank you for viewing the detailed overview of SSY Group's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


SSY Group (HKSE:02005) Business Description

Traded in Other Exchanges
N/A
Address
Central Plaza, 18 Harbour Road, Rooms 4902-03, 49th Floor, Wanchai, Hong Kong, HKG
SSY Group Ltd is engaged in the research, development, manufacturing and selling of a wide range of pharmaceutical products, which includes finished medicines of mainly intravenous infusion solution and ampoule injection to hospitals and distributors, bulk pharmaceuticals and medical materials. The company has two reportable segments including intravenous infusion solution and others and medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products, followed by medical materials.

SSY Group (HKSE:02005) Headlines

No Headlines